Advertisement

Pfizer’s COVID-19 Vaccine Works Against New UK Variant

The good news couldn't come sooner.

Pfizer has stated that its COVID-19 vaccine works against the new strands of the coronavirus first discovered in the U.K. and South Africa.

A new study, that has yet to be peer-reviewed, about Pfizer and BioNTech's COVID-19 vaccine revealed that it appears to work against the new coronavirus variants found in the U.K. and South Africa.

The study was led by Pfizer and the University of Texas Medical Branch, as reported by Reuters.

SEE ALSO: CEO BIONTECH 'CONFIDENT' COVID-19 VACCINE CAN WORK ON UK VARIANT

There have been doubts about whether or not COVID-19 vaccines would work against the new strand of the virus, but now it's looking likely that some do, and even late last year AstraZeneca stated its vaccine "likely works against the new variant." 

The new study indicated that the vaccine worked in neutralizing the new mutation of the spike protein.

There have been fears that the new mutation has a greater transmissibility rate and, that it could also make the virus escape antibody neutralization brought on by the vaccine, as one of Pfizer's top viral vaccine scientists, Phil Dormitzer, said.

The new study took blood samples of people who had already been given the vaccine. However, it should be taken with a grain of salt, as its findings are currently still limited. The study did not go into the entire set of mutations found in both new variants of the virus. 

"So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” Dormitzer stated. “That doesn’t mean that the 17th won’t," he continued.

Advertisement

The team of scientists plans on carrying out more tests to ensure the vaccine is effective against other mutations found in the U.K. and the South African variants. The hope is to have more information in the coming weeks. 

Follow Us on

Stay on top of the latest engineering news

Just enter your email and we’ll take care of the rest:

By subscribing, you agree to our Terms of Use and Privacy Policy. You may unsubscribe at any time.